Literature DB >> 30777199

Whole-tumour histogram analysis of pharmacokinetic parameters from dynamic contrast-enhanced MRI in resectable oesophageal squamous cell carcinoma can predict T-stage and regional lymph node metastasis.

Yan-Li Chen1, Rui Li2, Tian-Wu Chen3, Jing Ou2, Xiao-Ming Zhang2, Fan Chen1, Lan Wu2, Yu Jiang2, Maxwell Laws4, Kamran Shah4, Bobby Joseph4, Jiani Hu4.   

Abstract

OBJECTIVE: To identify whether whole-tumour histogram analysis of pharmacokinetic parameters from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) could predict T-stage and regional lymph node metastasis (LNM) of resectable oesophageal squamous cell carcinoma (SCC).
MATERIALS AND METHODS: Forty-two consecutive patients with confirmed oesophageal SCC underwent thoracic DCE-MRI. Histogram metrics (median, mean, standard deviation [SD], skewness, kurtosis and entropy) of whole-tumour pharmacokinetic parameters including endothelial transfer constant (Ktrans), reflux rate (Kep) and fractional extravascular extracellular space volume (Ve) were generated by the Omni-Kinetics software. Histogram datasets were interpreted using the Mann-Whitney U test and receiver operating characteristic (ROC) statistical analyses.
RESULTS: The Mann-Whitney U tests revealed that the median, mean and SD of Ktrans, the SD and entropy of Kep, and the median, mean and entropy of Ve of T1-2 stage oesophageal SCC were lower when compared with T3 stage (all Ps < 0.05); and the ROC analysis showed that the entropy of Ve could reliably distinguish T1-2 stage from T3 stage with an area under ROC (AUC) of 0.773. The Mann-Whitney U tests illustrated that the entropy of Ktrans, and the median, mean, SD and entropy of Kep were higher while the skewness of Kep was lower in tumours with LNM than without LNM (all Ps < 0.05); and the ROC analysis demonstrated that the SD of Kep could best identify tumours with LNM with an AUC of 0.702.
CONCLUSION: Whole-tumour histogram analysis of pharmacokinetic parameters of oesophageal SCC on DCE-MRI could be used to predict T-stage and regional LNM.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Esophagus; Lymphatic metastasis; Magnetic resonance imaging; Perfusion imaging; Squamous cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30777199     DOI: 10.1016/j.ejrad.2019.01.012

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Wenbing Ji; Jian Wang; Rongzhen Zhou; Minke Wang; Weizhen Wang; Peipei Pang; Min Kong; Chao Zhou
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

2.  Predicting T and N Staging of Resectable Gastric Cancer According to Whole Tumor Histogram Analysis About a Non-Cartesian k-Space Acquisition DCE-MRI: A Feasibility Study.

Authors:  Liangliang Yan; Jinrong Qu; Jing Li; Hongkai Zhang; Yanan Lu; Jianbo Gao
Journal:  Cancer Manag Res       Date:  2021-10-18       Impact factor: 3.989

Review 3.  The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer.

Authors:  Anna Pellat; Anthony Dohan; Philippe Soyer; Julie Veziant; Romain Coriat; Maximilien Barret
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

4.  Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT.

Authors:  Fei Wang; Rui Guo; Yan Zhang; Boqi Yu; Xiangxi Meng; Hanjing Kong; Yang Yang; Zhi Yang; Nan Li
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

5.  Quantitative perfusion histogram parameters of dynamic contrast-enhanced MRI to identify different pathological types of uterine leiomyoma.

Authors:  Subo Wang; Zhenhua Zhao; Yu Zhang; Liming Yang; Yanan Huang; Yawen Ruan; Cheng Wang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.